Techtran Polylenses Peer Comparison
BSE: 523455
₹3.43
₹0.16
(4.89%)
As on 12-Jun-2017IST
Market cap
₹5 Cr
Revenue (TTM)
₹6 Cr
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Edit
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
5 | 17,553 | 1,281 | 582 | 316 |
Revenue (₹ Cr) |
6 | 1,997 | 314 | 92 | 153 |
Net Profit (₹ Cr) |
-12.68 | 307.01 | 24.51 | 4.71 | 4.34 |
Net Margin (%) |
-209.24 | 14.56 | 7.60 | 5.06 | 2.70 |
RoE (%) |
-65.79 | 10.63 | 13.94 | 4.92 | 2.29 |
Price to Earnings |
-- | 55.71 | 22.98 | 47.39 | 72.90 |
Price-To-Book |
0.40 | 5.52 | 6.05 | 4.17 | 1.72 |
Income Statement (₹ Cr)
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
|
Operating Revenue
|
22.84 | 390.35 | -- | -- | -- |
|
Total Income
|
23.83 | 398.47 | -- | -- | -- |
|
Total Expenditure
|
25.19 | 304.27 | -- | -- | -- |
|
EBITDA
|
-2.35 | 86.08 | -- | -- | -- |
|
Depreciation
|
2.51 | 18.77 | -- | -- | -- |
|
EBIT
|
-4.86 | 67.31 | -- | -- | -- |
|
Interest
|
0.88 | 10.25 | -- | -- | -- |
|
Other Income
|
0.99 | 8.12 | -- | -- | -- |
|
Exceptional Items
|
-- | 19.58 | -- | -- | -- |
|
Profit before Tax
|
-4.76 | 84.75 | -- | -- | -- |
|
Provision for Tax
|
0.08 | 23.10 | -- | -- | -- |
|
Profit after Tax
|
-4.83 | 61.65 | -- | -- | -- |
Liabilities (₹ Cr)
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
26.25 | 196.18 | -- | -- | -- |
|
Minority Interest
|
0.71 | 0.00 | -- | -- | -- |
|
Non-Current Liabilities
|
1.98 | 55.22 | -- | -- | -- |
|
Current Liabilities
|
22.37 | 112.62 | -- | -- | -- |
|
Total Liabilities
|
51.30 | 364.02 | -- | -- | -- |
Assets (₹ Cr)
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
30.68 | 204.51 | -- | -- | -- |
|
Current Assets
|
20.62 | 159.50 | -- | -- | -- |
|
Total Assets
|
51.30 | 364.02 | -- | -- | -- |
|
Total Debt*
|
10.46 | 78.81 | -- | -- | -- |
|
Net Current Assets
|
-1.75 | 46.88 | -- | -- | -- |
|
Contingent Liabilities
|
2.47 | 37.30 | -- | -- | -- |
Cashflow (₹ Cr)
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
4.95 | 63.30 | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-2.87 | -59.33 | -- | -- | -- |
|
Cash from Financing Activities
|
-1.85 | -5.89 | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
0.22 | -1.91 | -- | -- | -- |
Ratios
Profitability Ratios
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-9.80 | 38.90 | -- | -- | -- |
|
ROE (%)
|
-16.93 | 36.03 | -- | -- | -- |
|
ROA (%)
|
-9.25 | 18.97 | -- | -- | -- |
|
EBIT Margin (%)
|
-5.97 | 24.13 | -- | -- | -- |
|
Net Margin (%)
|
-20.29 | 15.47 | -- | -- | -- |
|
Cash Profit Margin (%)
|
-9.87 | 20.35 | -- | -- | -- |
Growth Ratios
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-31.78 | 21.13 | -- | -- | -- |
|
EBIT Growth (%)
|
-151.16 | 22.71 | -- | -- | -- |
|
Net Profit Growth (%)
|
-325.35 | 40.02 | -- | -- | -- |
|
EPS Growth (%)
|
-778.76 | 38.06 | -- | -- | -- |
|
Book Value Growth (%)
|
-14.99 | 34.33 | -- | -- | -- |
Valuation Ratios
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 17.72 | -- | -- | -- |
|
Price / Book Value
|
0.87 | 11.26 | -- | -- | -- |
|
Dividend Yield (%)
|
0.00 | 0.50 | -- | -- | -- |
|
EV/EBITDA
|
-23.74 | 24.07 | -- | -- | -- |
|
Market Cap (₹ Cr)
|
22.77 | 2,208.31 | -- | -- | -- |
Solvency Ratios
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.40 | 0.40 | -- | -- | -- |
|
Short term debt to equity ratio
|
0.39 | 0.11 | -- | -- | -- |
|
Current Ratio
|
0.92 | 1.42 | -- | -- | -- |
|
Quick Ratio
|
0.37 | 0.90 | -- | -- | -- |
|
Interest Coverage
|
-4.39 | 9.27 | -- | -- | -- |
Operating Efficiency Ratios
| Techtran Polylenses | Poly Medicure | Q-Line Biotech | Saakshi Medtech | Nureca | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
29.79 | 16.09 | -- | -- | -- |
|
Asset Turnover
|
0.45 | 1.22 | -- | -- | -- |
|
Receivable days
|
126.73 | 50.14 | -- | -- | -- |
|
Inventory Days
|
189.98 | 46.02 | -- | -- | -- |
|
Payable days
|
339.42 | 113.87 | -- | -- | -- |
|
Cash Conversion Cycle
|
-22.71 | -17.71 | -- | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
